Home Analysts Viewpoint EVP Chief Legal Off & Corp Sec ALEXANDER SUSAN H sale 5,532 shares of Biogen Inc. [BIIB]

EVP Chief Legal Off & Corp Sec ALEXANDER SUSAN H sale 5,532 shares of Biogen Inc. [BIIB]

0
EVP Chief Legal Off & Corp Sec ALEXANDER SUSAN H sale 5,532 shares of Biogen Inc. [BIIB]
ZOM Stock

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Biogen Inc. shares valued at $1,552,832 were sold by ALEXANDER SUSAN H on Oct 27. At $280.70 per share, ALEXANDER SUSAN H sold 5,532 shares. The insider’s holdings dropped to 39,396 shares worth approximately $11.04 million following the completion of this transaction.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Also, BIOGEN INC. sold 100,000 shares, netting a total of over 526,520 in proceeds. Following the sale of shares at $5.27 each, the insider now holds 23,652,466 shares.

Before that, BIOGEN INC. had sold 400,000 shares from its account. In a trade valued at $2,130,720, the 10% Owner traded Biogen Inc. shares for $5.33 each. Upon closing the transaction, the insider’s holdings decreased to 400,000 shares, worth approximately $6.66 billion.

As published in a research note from Goldman on October 26, 2022, Biogen Inc. [BIIB] has been rated up from a Neutral to a Buy and the price target has been revised to $370 from $220. This represents a 24.26% premium over Thursday’s closing price. Analysts at Stifel upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid October. As of October 07, 2022, Argus has increased its “Hold” rating to a “Buy” for BIIB. Earlier on September 28, 2022, Robert W. Baird upgraded its rating. Their new recommendation was “an Outperform” for BIIB stock which previously was a “a Neutral”.

Analyzing BIIB Stock Performance

On Thursday, Biogen Inc. [NASDAQ: BIIB] rose 0.68% to $280.25. The stock’s lowest price that day was $274.63, but it reached a high of $282.5899 in the same session. During the last five days, there has been a surge of approximately 0.86%. Over the course of the year, Biogen Inc. shares have jumped approximately 16.81%. Shares of the company reached a 52-week high of $287.37 on 11/02/22 and a 52-week low of $187.16 on 05/09/22. A 50-day SMA is recorded $238.19, while a 200-day SMA reached $216.85. Nevertheless, trading volume fell to 0.87 million shares from 1.5 million shares the previous day.

Support And Resistance Levels for Biogen Inc. (BIIB)

According to the 24-hour chart, there is a support level at 275.72, which, if violated, would cause prices to drop to 271.20. In the upper region, resistance lies at 283.68. The next price resistance is at 287.12. RSI (Relative Strength Index) is 64.55 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 4.74, which suggests the price will increase in the coming days. Percent R is at 26.33%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Biogen Inc. subject to short interest?

Stocks of Biogen Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.57 million shares to 2.09 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 2.66 million shares. A decline of -27.27% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.91 of the overall float, the days-to-cover ratio (short ratio) decline to 1.91.

Which companies own the most shares of Biogen Inc. (BIIB)?

According to PRIMECAP Management Co. filings, the company currently owns 15,726,526 shares, which is about 10.84% of the total BIIB shares outstanding. The investor’s shares have plunged by -108,080 from its previous 13-F filing of 15834606.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $3,007,801,992. BlackRock Fund Advisors acquire a 8.50% interest valued at $2.26 billion while SSgA Funds Management, Inc. sold a -332,025 stake. A total of 37,199 shares of Biogen Inc. were sold by Wellington Management Co. LLP during the quarter, and 438,859 were bought by Geode Capital Management LLC. In its current portfolio, BlackRock Investment Management holds 2,140,501 shares valued at $571.51 million.

In terms of Biogen Inc. share price expectations, FactSet research, analysts set an average price target of $306.04 in the next 12 months, up nearly 9.57% from the previous closing price of $278.37. Analysts anticipate Biogen Inc. stock to reach $370.00 by 2022, with the lowest price target being $218.00. In spite of this, 33 analysts ranked Biogen Inc. stock as an Overweight at the end of 2022. On September 28, 2022, Mizuho assigned a price target of “a Buy” to the stock and upgraded coverage with a $270.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]